Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). 1,600,000 shares priced at $125.00/share; underwriters hold 30-day option for additional 240,000 shares.
PALVELLA THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- 1,600,000 shares priced at $125.00/share; underwriters hold 30-day option for additional 240,000 shares
- Net proceeds ~$187.3M after underwriting discounts and offering expenses
- All shares sold by the Company: primary offering, fully dilutive to existing shareholders
- Proceeds earmarked for QTORIN rapamycin and QTORIN pitavastatin development plus R&D and working capital
- Expected close ~Feb 27, 2026; underwriters: TD Securities, Cantor Fitzgerald, Stifel Nicolaus
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PALVELLA THERAPEUTICS, INC. 8-K filings
Get the next PVLA 8-K as it lands
Follow PVLA for push alerts, or ask the research agent what this filing means.